Would you give/omit regional nodal irradiation in low nodal burden ER- Her2+ disease s/p BCS with SLNB?   

e.g. Gringas et al., JNCI 2017, a secondary analysis of the ALTTO trial?



Answer from: Radiation Oncologist at Academic Institution